We sought to develop a proteomics-based risk model for lung cancer and evaluate its risk-discriminatory performance in comparison with a smoking-based risk model (PLCOm2012) and a commercially available autoantibody biomarker test.
Tópico:
Lung Cancer Treatments and Mutations
Citaciones:
9
Citaciones por año:
Altmétricas:
0
Información de la Fuente:
FuenteJNCI Journal of the National Cancer Institute
